自付费用、种族/民族与医疗保险乳腺癌患者辅助内分泌治疗依从性的关联
该回顾性队列研究利用SEER-Medicare数据库纳入2007至2009年参加Medicare Part D的65岁及以上激素受体阳性乳腺癌患者,评估1年辅助内分泌治疗依从性。8688例中3197例(36.8%)不依从。调整自付费用、贫困状态和合并症后,西班牙裔和黑人与非西班牙裔白人依从性差异不再显著,种族/民族差异很大程度上由社会经济状况和自付药物费用差异解释。
要点
- 8688例中3197例(36.8%)对辅助内分泌治疗不依从。
- 调整后西班牙裔(OR 0.95;95%CI 0.78-1.17)和黑人(OR 0.96;95%CI 0.77-1.19)依从性差异不再显著。
- 黑人以他莫昔芬起始辅助内分泌治疗时调整后依从性低于非西班牙裔白人(OR 0.54;95%CI 0.31-0.93)。
核心结论
- 辅助内分泌治疗依从性的种族/民族差异很大程度上由社会经济状况和自付药物费用差异解释。
研究设计与样本
- 回顾性队列研究,使用SEER-Medicare关联数据库,纳入2007至2009年参加Medicare Part D的65岁及以上激素受体阳性乳腺癌患者,队列包括非西班牙裔白人、黑人、西班牙裔和亚裔。
主要发现
- 8688例患者中3197例(36.8%)对辅助内分泌治疗不依从。
- 与最低费用类别≤2.65美元相比,所有四个较高自付费用类别均与较低调整后依从比值相关(P<.01)。
- 单变量分析中,西班牙裔起始任何辅助内分泌治疗时依从比值高于非西班牙裔白人(OR 1.30;95%CI 1.07-1.57),黑人起始芳香化酶抑制剂时依从比值高于非西班牙裔白人(OR 1.27;95%CI 1.04-1.54)。
- 调整共付额、贫困状态和合并症后,西班牙裔(OR 0.95;95%CI 0.78-1.17)和黑人(OR 0.96;95%CI 0.77-1.19)的依从性差异不再显著。
- 调整社会经济、临床和预后因素后,黑人以他莫昔芬起始辅助内分泌治疗时调整后依从比值显著低于非西班牙裔白人(OR 0.54;95%CI 0.31-0.93)。
关键数值与推荐
- 依从性采用12个月期间药物持有率≥80%评估。
- 自付费用按30天供应量标准化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Previous studies suggest that adherence to adjuvant endocrine therapy (AET) for patients with breast cancer is suboptimal, especially among minorities, and is associated with out-of-pocket medication costs. This study aimed to determine whether there are racial/ethnic differences in 1-year adherence to AET and whether out-of-pocket costs explain the racial/ethnic disparities in adherence. Methods This retrospective cohort study used the SEER-Medicare linked database to identify patients ≥ 65 years of age with hormone receptor-positive breast cancer who were enrolled in Medicare Part D from 2007 to 2009. The cohort included non-Hispanic whites, blacks, Hispanics, and Asians. Out-of-pocket costs for AET medications were standardized for a 30-day supply. Adherence to tamoxifen, aromatase inhibitors (AIs), and overall AET (tamoxifen or AIs) was assessed using the medication possession ratio (≥ 80%) during the 12-month period. Results Of 8,688 patients, 3,197 (36.8%) were nonadherent to AET. Out-of-pocket costs for AET medication were associated with lower adjusted odds of adherence for all four cost categories compared with the lowest category of ≤ $2.65 ( P < .01). In the univariable analysis, Hispanics had higher odds of adherence to any AET at initiation (OR, 1.30; 95% CI, 1.07 to 1.57), and blacks had higher odds of adherence to AIs at initiation (OR, 1.27; 95% CI, 1.04 to 1.54) compared with non-Hispanic whites. After adjusting for copayments, poverty status, and comorbidities, the association was no longer significant for Hispanics (OR, 0.95; 95% CI, 0.78 to 1.17) or blacks (OR, 0.96; 95% CI, 0.77 to 1.19). Blacks had significantly lower adjusted odds of adherence than non-Hispanic whites when they initiated AET therapy with tamoxifen (OR, 0.54; 95% CI, 0.31 to 0.93) after adjusting for socioeconomic, clinic, and prognostic factors. Conclusion Racial/ethnic disparities in AET adherence were largely explained by women's differences in socioeconomic status and out-of-pocket medication costs.
引用
- Farias AJ, Du XL. Association Between Out-Of-Pocket Costs, Race/Ethnicity, and Adjuvant Endocrine Therapy Adherence Among Medicare Patients With Breast Cancer. J Clin Oncol. 2016. PMID: 28034069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。